Cyclooxygenase inhibition and thrombogenicity

American Journal of Medicine

Volumn 110, Issue 3 SUPPL. 1, 2001, Pages 28-32

  Catella Lawson, Francesca ^a   Crofford, Leslie J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; THROMBOXANE A2;

ANTICOAGULATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOGENICITY;

EID: 0035910976     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(00)00683-5     Document Type: Review

References (45)

1. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides
2. Platelet activation in unstable coronary disease
3. 2 formation in the human circulation
4. Increased thromboxane biosynthesis in a human preparation of platelet activation: Biochemical and functional consequences of selective inhibition of thromboxane synthase
5. 2 metabolites in humans
6. Diabetes mellitus, hypercholesterolemia and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease
7. Secondary prevention of vascular disease by prolonged antiplatelet treatment
8. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
9. 2 (prostacylin) by cultured human and bovine endothelial cells
10. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla
11. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
12. A double-blind placebo-controlled evaluation of prostacyclin in man
13. Oral iloprost as a treatment for Raynaud's syndrome: A double blind multicentre placebo controlled study
14. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis
15. Increased prostacyclin biosynthesis is increased in patients with severe atherosclerosis and platelet activation
16. Effects of selective inhibition of cyclooxygenase II on sodium balance, hemodynamics, and vasoactive eicosanoids
17. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
18. 2 biosynthesis in cardiovascular disease
19. Measurement of renal and nonrenal eicosanoid synthesis
20. 2 production in patients with systemic lupus erythematosus
21. The metabolic disposition of prostacyclin in man
22. Estimated rate of prostacyclin secretion into the circulation of normal man
23. Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin
24. Clinical pharmacology of platelet cyclooxygenase inhibition
25. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects
26. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
27. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs
28. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
29. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction
30. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study
31. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women
32. Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol)
33. 2 in man under normal conditions, following drugs and during some pathological conditions
34. Ibuprofen, but not rofecoxib or acetaminophen, antagonizes the irreversible anti-platelet effect of aspirin
35. Cardiovascular safety profile of rofecoxib in controlled clinical trials
36. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial
37. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases
38. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs
39. Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding
40. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy
41. 2 synthase cyclooxygenase active site
42. 2 synthase
43. Salicylate reverses in vitro aspirin inhibition of rat platelet and vascular prostaglandin generation
44. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity
45. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin